PEAK6 Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

PEAK6 Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-29,200	Closed	-$5.19M	–	5447
2021 Q2	$5.19M	Hold	29,200	–	–	0.01%	1082
2021 Q1	$4.8M	Buy	+29,200	New	+$4.8M	0.01%	1110
2020 Q4	–	Sell	-35,400	Closed	-$5.05M	–	4851
2020 Q3	$5.05M	Hold	35,400	–	–	0.01%	937
2020 Q2	$3.91M	Sell	35,400 -23,500	-40%	-$2.6M	0.01%	972
2020 Q1	$5.88M	Buy	58,900 +55,800	+1,800%	+$7.21M	0.03%	479
2019 Q4	$463K	Sell	3,100 -13,700	-82%	-$1.86M	﹤0.01%	2031
2019 Q3	$2.15M	Sell	16,800 -12,500	-43%	-$1.68M	0.01%	1222
2019 Q2	$4.18M	Buy	29,300 +10,900	+59%	+$1.46M	0.03%	815
2019 Q1	$2.63M	Sell	18,400 -10,400	-36%	-$1.36M	0.02%	1120
2018 Q4	$3.57M	Buy	28,800 +7,200	+33%	+$1.07M	0.02%	851
2018 Q3	$3.63M	Buy	+21,600	New	+$3.71M	0.02%	986

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

PEAK6 Investments's JAZZ Position: Q3 2021 in Review

PEAK6 Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 4,157 shares — an estimated $739K sold.

PEAK6 Investments first reported a position in JAZZ in Q3 2018 and held it in 9 quarters. The position peaked at $2.35M in Q4 2018. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

PEAK6 Investments reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
PEAK6 Investments sold 4,157 Jazz Pharmaceuticals shares in Q3 2021, an estimated $739K.
PEAK6 Investments first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 9 quarters.
PEAK6 Investments's Jazz Pharmaceuticals position peaked at $2.35M in Q4 2018.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on PEAK6 Investments's 13F filing for Q3 2021, filed 12 Nov 2021.